Next Article in Journal
Demographic Characteristics and Inflammatory Biomarker Profile in Psoriatic Arthritis Patients with Comorbid Fibromyalgia: A Cross-Sectional Study
Previous Article in Journal
Terpinen-4-ol Targets HIF-1α/TGF-β1/TNF-α Axis to Attenuate Ethanol-Induced Hepatotoxicity: Network Pharmacology and In Vitro Validation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Helicobacter pylori Seroprevalence and Its Associations with Sociodemographic Characteristics, Environmental Factors, and Gastrointestinal Complaints: A Cross-Sectional Study in the Adult Population of Kaunas City, Lithuania

1
Department of Gastroenterology, Lithuanian University of Health Sciences, Eiveniu Str. 2, 50009 Kaunas, Lithuania
2
Health Research Institute, Lithuanian University of Health Sciences, Tilzes Str. 18, 47181 Kaunas, Lithuania
3
Institute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu Str. 4, 50103 Kaunas, Lithuania
4
Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu av. 15, 50103, Kaunas, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2025, 61(6), 1049; https://doi.org/10.3390/medicina61061049
Submission received: 4 May 2025 / Revised: 29 May 2025 / Accepted: 4 June 2025 / Published: 6 June 2025
(This article belongs to the Section Gastroenterology & Hepatology)

Abstract

Background and Objectives: Helicobacter pylori, classified as a Group I carcinogen, is the main risk factor for gastric cancer, one of the leading causes of cancer mortality globally. Lithuania reports one of the highest gastric cancer rates in Europe, yet recent large-scale epidemiological data on H. pylori prevalence are lacking. This study aimed to assess the current seroprevalence of H. pylori in Lithuanian adults and its associations with sociodemographic, environmental factors, and dyspeptic symptoms. Materials and Methods: A cross-sectional study was conducted between 2020 and 2023 at the Lithuanian University of Health Sciences in Kaunas city. Randomly selected adults aged 25–69 years underwent venous blood sampling for H. pylori IgG antibody testing (Serion ELISA) and completed a questionnaire on demographic–environmental factors and dyspeptic symptoms in the past 30 days. Subjects previously treated for H. pylori were excluded from seroprevalence analysis. Seroprevalence was compared across age groups using χ2 and Z-tests with Bonferroni correction. Multivariable logistic regression identified factors associated with H. pylori seropositivity. The selected level of statistical significance was p < 0.05. Results: A total of 1046 adults (mean age 47.2 years, SD = 11.5; 50% males) participated in the study. The overall age-standardized H. pylori seroprevalence was 63.1% (95% CI 60.4–66.7). Seropositivity increased with age, peaking at 80.3% in males aged 55–69. Higher seroprevalence was observed among those with basic education and those lacking access to municipal or heated water during childhood. Regression analysis revealed that male sex, aging, and lower education were significantly associated with H. pylori seropositivity. No significant link was found between H. pylori seroprevalence and gastrointestinal complaints. Conclusions: H. pylori seroprevalence remains high in Lithuanian adults, highlighting the need for ongoing surveillance and consideration of screening strategies. H. pylori infection was linked to sociodemographic and environmental factors but not dyspeptic complaints.

1. Introduction

Helicobacter pylori (H. pylori) is a Gram-negative bacterium that colonizes the human stomach and has the ability to persist for decades. It is recognized as one of the most common chronic bacterial infections worldwide. Even though many carriers remain asymptomatic, chronic infection may lead to severe gastric diseases. This bacterium is the primary cause of chronic gastritis and is associated with numerous conditions, such as gastric cancer (GC), peptic ulcer disease (PUD), mucosa-associated lymphoid tissue lymphoma, and others [1,2,3]. Moreover, H. pylori, which was classified as a definite (Group I) carcinogen by the International Agency for Research on Cancer (IARC) in 1994, is the biggest risk factor in the etiopathogenesis of non-cardia GC—one of the leading causes of cancer-related deaths globally [4]. According to the Global Cancer Observatory (GLOBOCAN) database from 2022, GC ranks fifth in both incidence and mortality among various types of cancer [5].
Although the prevalence of H. pylori globally is declining, it is estimated that approximately 40–50% of the World’s population is still infected with this bacterium. Higher prevalence rates are observed in developing countries with poor sanitation and crowded living conditions, as well as low socioeconomic status, whereas developed Western countries have lower prevalence rates [3,6,7]. This bacterial infection is typically acquired in childhood through an oral–oral or fecal–oral transmission route. Socioeconomic factors such as sanitation, access to clean water, and education level influence the risk of acquiring H. pylori infection, while lifestyle factors like diet, smoking, and alcohol consumption may affect the progression of H. pylori-associated conditions [8].
There is a lack of epidemiological data on H. pylori in Eastern and Central European countries, including Lithuania. A population-based epidemiological study in Latvia revealed a high (79.2%) prevalence of H. pylori infection [9]. In the Tartu population of Estonia, the prevalence of H. pylori antibodies was found to be 69% [10]. Similarly, in the neighboring Poland, 78.5% of randomly selected residents in Lublin tested positive for H. pylori [11]. The prevalence of H. pylori infection in Lithuania and its associated conditions has been examined in several smaller studies, with rates ranging from 36% in children to approximately 70% in middle-aged adults with dyspeptic symptoms. One of the more recent studies revealed a dramatic decrease in the seroprevalence of H. pylori over 25 years among Lithuanian medical students, from 52% in 1995 to 14% in 2020 [12,13,14,15]. However, epidemiological data on the general population in Lithuania remain very limited.
Furthermore, the incidence of GC in Lithuania remains one of the highest in Europe, with an age-standardized rate per 100,000 inhabitants of 18.4 in males and 7.2 in females based on the GLOBOCAN 2022 data [5]. The high burden of GC in Lithuania and neighboring countries highlights the critical public health importance of addressing H. pylori infection and the need for ongoing surveillance and effective management strategies [16].
The European guidelines for H. pylori diagnostics and treatment are presented in the recently updated Maastricht VI/Florence Consensus Report, which is also followed in Lithuania. These guidelines state that validated serological tests for IgG anti-H. pylori antibodies can be used for primary diagnosis in cases when endoscopy is not indicated, and there is no history of previous H. pylori eradication [1]. A recent study using data from the European Registry on H. pylori Management (Hp-EuReg) in Lithuania concluded that the diagnostics and treatment of H. pylori infection only partially met international guidelines [17].
Therefore, this study aimed to assess the seroprevalence of Helicobacter pylori infection in the adult population of Kaunas city, Lithuania, and analyze its associations with sociodemographic and environmental factors, as well as dyspeptic symptoms, in a broader cohort.

2. Materials and Methods

2.1. Study Setting and Ethics

The seroprevalence of H. pylori IgG antibodies was assessed in a study entitled “Chronic Diseases and their Risk Factors in the Adult Population”. This study was conducted among residents of Kaunas, the second-largest city in Lithuania, aged 25 to 69 years. A random sample of Kaunas males and females aged 25–69 years, stratified by sex and age, was randomly selected from the Lithuanian population register (n = 6000). The study began in 2020 but was interrupted due to the COVID-19 pandemic and resumed in 2023. In total, 3426 individuals participated in the study until 21 June 2024. The response rate was 57.1%. H. pylori IgG antibodies were assessed in a subsample of individuals who were screened by 23 June 2023. Invitations were mailed to the selected individuals to come for a health check-up at the Hospital of Lithuanian University of Health Sciences (LUHS) Kaunas Clinics.
The study was approved by the Kaunas Regional Biomedical Research Ethics Committee (protocol number BE-2-49, issued on 5 June 2018). Written informed consent was obtained from all participants.

2.2. Study Subjects

By 23 June 2023, blood serum samples from 1046 participants were tested for H. pylori IgG antibodies. The H. pylori study population comprised 526 males (50.3%) and 520 females (49.7%). The mean age of the participants was 47.2 years, with a standard deviation of 11.5 years.

2.3. Data Collection and Variables

All study participants completed a questionnaire that included questions about factors potentially associated with the prevalence of H. pylori infection. The questionnaire covered the following factors: (1) social and demographic characteristics, such as sex, age, marital status, level of education, and place of residence during childhood; (2) environmental factors, including the number of family members during childhood, the source of drinking water, and access to hot tap water in childhood; and (3) dyspeptic complaints. Participants were categorized into four age groups: 25–34, 35–44, 45–54, and 55–69 years old. They were also grouped into three groups based on education level: (1) basic education: primary, incomplete secondary, and secondary education; (2) intermediate education: technical school or vocational training; (3) advanced education: college or university degree (bachelor’s, master’s or doctoral degree).
Participants were asked if they had previously been tested for H. pylori. The possible responses were “no”, “yes, the bacterium was not detected”, “yes, the bacterium was detected”, and “I don’t know”. The subsequent question was “If you have been diagnosed with H. pylori, have you used any medications to eradicate the bacteria?” The possible answers were “no”, “yes”, and “I don’t know”.
Additionally, participants were asked binary (yes/no) questions if they had experienced dyspeptic complaints within the past 30 days, including epigastric pain, heartburn, nausea/vomiting, diarrhea, and constipation. The intensity of the symptoms was not evaluated.

2.4. H. pylori IgG Antibodies Testing

A blood sample was collected from a peripheral vein to test for H. pylori IgG antibodies. Human IgG antibodies against H. pylori were detected in serum using a diagnostic quantitative enzyme-linked immunosorbent assay (ELISA) kit (SERION ELISA® Classic Helicobacter pylori IgG, Wurzburg, Germany), following the manufacturer’s protocol. The optical density of the reaction solution was measured using a Sunrise microplate reader (Tecan Trading AG, Zurich, Switzerland) at a wavelength of 405 nm, with a reference wavelength of 620 nm. Measurements were analyzed using Magellan™ Standard software (Tecan Trading AG, Zurich, Switzerland).

2.5. Exclusion from Further Analysis

In total, 132 participants answered that they had previously received H. pylori eradication therapy. In this study, we had no access to the medical history or records of study participants; therefore, we could not ensure that they had really been previously diagnosed with H. pylori infection, received eradication therapy, or if the eradication success had been confirmed. To avoid any inaccurate data, these subjects were excluded from the analysis of current seroprevalence and its associations with other independent factors.

2.6. Statistical Analysis

Statistical analysis was performed using the statistical package IBM SPSS Statistics 27.0 (IBM Corp.: Armonk, NY, USA, released 2020).
The prevalence of H. pylori IgG antibodies was expressed in percentages. The proportions of H. pylori seropositive individuals in different groups were compared using a χ2 test and Z-test with Bonferroni correction for multiple comparisons. To calculate the total prevalence of H. pylori IgG antibodies, the indicators were standardized by age using the age structure of the Kaunas city population as the reference.
A logistic regression analysis was conducted to assess the association between H. pylori antibody positivity (the dependent variable) and various sociodemographic and environmental factors. Initially, separate models were created for each variable. Following that, all variables—such as sex, age, education, and childhood environmental conditions (including living location, access to tap water, and hot water supply)—were combined into a single model for multivariable analysis. The selected level of statistical significance was p < 0.05.

3. Results

3.1. Demographic and Socioeconomic Data

A total of 1046 residents from Kaunas participated in the H. pylori seroprevalence study. The largest age group was 55–69 years old (30.3%), comprising 28.9% of total males and 31.7% of total females. The smallest age group was 25–34 years old (17.1%), accounting for 19.2% of total males and 15% of total females. Over half (59%) of the participants had attained advanced education. Notably, 75.8% of the participants reported having grown up in urban areas and having access to centralized drinking water and hot tap water during childhood. Additionally, almost half of the study participants (47.9%) grew up in households with four members. Detailed demographic and environmental data are shown in Table 1.

3.2. Seroprevalence of H. pylori IgG Antibodies

The age-standardized seroprevalence of H. pylori IgG antibodies in the population of Kaunas city, aged 25–69 years, was 63.1% (95% CI 60.4–66.7). H. pylori seroprevalence was higher in males (66.3%) compared to females (60.2%). Statistically significant differences in seroprevalence between males and females were observed in the oldest age group (55–69 years). Overall, the proportion of seropositive individuals increased with age, particularly among males. The highest seroprevalence of IgG H. pylori antibodies was observed among men aged 55–69 years (80.3%) and women aged 45–54 years (67.2%). Conversely, the lowest prevalence was found in the youngest age group (25–34 years old), with about 48% in both genders. The detailed seroprevalence of H. pylori and the comparison between different age groups is presented in Table 2.

3.3. Seroprevalence of H. pylori Antibodies in Relation to the Analyzed Independent Factors

The prevalence of Helicobacter pylori IgG antibodies was statistically significantly higher among participants with basic education compared to those with intermediate or advanced education. Participants who had access to tap water and hot water during childhood had a statistically significantly lower prevalence of H. pylori compared to those having no access to a municipal water supply or heated water. The place of residence and the number of household members during childhood did not influence the prevalence of H. pylori infection. Detailed information is presented in Table 3.
Univariable logistic regression analysis indicated that males had higher odds of H. pylori infection compared to females, and the likelihood of infection increased with age (Table 4). The highest odds of infection were found among respondents with the lowest level of education. Additionally, individuals who experienced poor hygienic conditions during childhood, specifically those without access to tap water or a hot water supply, had greater odds of seropositivity.
A multivariable logistic regression analysis confirmed that being male and older age were positively associated with the odds of H. pylori seropositivity. In contrast, the odds of infection decreased as education levels increased. Furthermore, the associations between H. pylori antibody positivity and the source of drinking water, as well as access to hot water during childhood, were found to be statistically non-significant. Detailed data are presented in Table 4.

3.4. History of Previous H. pylori Antibodies Testing and Eradication

Most participants (70.5%) reported that they had never been serologically tested for H. pylori. Nearly one in ten (11.6%) had been tested previously but received a negative result, while 15% tested positive. Among those who had been tested, the seroprevalence of H. pylori was 56.5% (157 out of 278 participants). Detailed data are presented in Table 5.

3.5. Dyspeptic Symptoms and Their Association with H. pylori Seroprevalence

Some of the participants reported experiencing gastrointestinal complaints in the past 30 days—around one-fifth of the participants experienced heartburn, which was the most frequent complaint. No statistically significant associations were found between the seroprevalence of H. pylori and gastrointestinal complaints, although there was a trend for these complaints to be more prevalent in H. pylori-seronegative participants (Figure 1).

4. Discussion

The findings of our study reveal the high seroprevalence of H. pylori infection in the city of Kaunas, Lithuania, and its associations with sociodemographic and environmental factors, as well as dyspeptic complaints. The overall age-standardized seroprevalence of H. pylori in our study (63.1%) likely reflects trends observed in neighboring countries as well; the most recent studies have shown a high H. pylori seroprevalence of 55% in Latvia, 84% in Polish adults, and approximately 60% in Ukrainian adults [18,19,20]. Our results confirm that the seroprevalence of H. pylori in Lithuania is markedly higher than that seen in Western Europe, where it is ~40%, emphasizing persistent disparities despite socioeconomic improvements. However, based on the previous local studies and the global trend of declining prevalence of H. pylori, we can estimate that the actual prevalence of H. pylori in Lithuania may be slightly lower than our current study findings suggest [13,14,15]. Some participants, who reported being treatment-naïve, might have actually been prescribed eradication therapy in the past, and a small number of patients were unaware of whether they had been tested for H. pylori or prescribed the treatment. A second diagnostic test in the H. pylori IgG-positive group could be considered to confirm the diagnosis.
Age-specific analysis in our study confirmed the “cohort effect”—the prevalence was higher among older cohorts. Our findings have shown a steady increase in prevalence with age, peaking at 80.3% in males aged 55–69, with the lowest prevalence in the youngest cohort of 25–34 years old. A higher prevalence in older populations and a declining prevalence among younger people in Lithuania have already been observed in previously published studies [12,13,14,15,17]. This trend reflects differences in exposure to poor sanitation during childhood, aligning with the “cohort effect” observed in global studies, where older populations exhibit higher H. pylori infection rates due to poorer socioeconomic conditions in their childhood [21].
Educational attainment emerged as one of the main determinants of H. pylori prevalence, with the highest rates observed among participants with basic education compared to those with advanced education. This association is consistent with most studies highlighting education as a proxy for better hygiene, nutrition, and healthcare access [22,23]. Access to drinking water was also associated with H. pylori prevalence: participants who relied on drinking water from wells had significantly higher infection rates compared to those using municipal water supplies. Similar trends were observed when evaluating access to hot water; its absence in childhood was associated with significantly higher prevalence. These findings also align with available evidence linking poor water quality and sanitation to higher infection rates. Interestingly, no significant differences were found when evaluating childhood living environment (urban vs. rural), contrary to available global data suggesting higher rates in rural areas [24,25,26,27].
The relationship between H. pylori and dyspeptic symptoms has been widely evaluated and discussed in existing studies, and the results are controversial. Even though some studies report a clear relationship between the prevalence of H. pylori and the intensity of dyspeptic symptoms [28], other studies do not support these findings [29], which was also a case in our current study.
The high seroprevalence of H. pylori in Lithuania, particularly among older and less educated populations, underscores the need for targeted public health interventions to reduce the incidence of GC and its associated health burden. Population screening and treatment for H. pylori infection to control gastric cancer has been proposed as a cost-effective strategy in high-risk populations [30,31]. This approach has already been successfully implemented in a few Asian countries [32]. As Lithuania belongs to a European area of high GC incidence, H. pylori screening and eradication programs focused on high-risk groups, along with efforts to improve socioeconomic conditions, could significantly reduce infection rates and the burden of GC. Currently, several European Union projects are ongoing in multiple European countries, evaluating the need for GC screening, possible implementation strategies, and providing essential missing evidence [16]. Lithuania is also a consortium member in some of these projects.
Finally, the strengths and limitations of our study need to be noted. Our research contributes to the epidemiological data of H. pylori in Lithuania and the surrounding region and is the largest-scale study evaluating the seroprevalence of this bacterial infection in our country to date. The high seroprevalence clearly indicates that a large proportion of the Lithuanian population is at a higher risk of developing GC; therefore, the results of this study might contribute to the process of implementing GC screening strategies in the near future, such as the “screen-and-treat” strategy. On the other hand, one of the main limitations of our research is the lack of access to official medical documentation on H. pylori diagnostics and eradication in previously treated subjects. Since we had to take the word of the study participants about any possible previous eradication prescriptions, these subjects were excluded from further analysis. Even though the number of such subjects was low (13%), if we had medical records of previous H. pylori diagnostics and treatment, this could have contributed to the evaluation of H. pylori IgG antibody titers after the treatment. Another limitation is related to the constraints of serology testing for H. pylori infection, as it may indicate a past infection rather than a current positive status for H. pylori. While serological testing is suitable for epidemiological studies at the population level, future research using stool antigen testing could provide a clearer understanding of the prevalence of H. pylori infection in the country.

5. Conclusions

The IgG seroprevalence of H. pylori in adult Kaunas residents aged 25–69 years was high. Higher infection rates were detected in respondents with lower educational attainment, lack of access to municipal water supplies, or lack of access to hot water in childhood. Our study confirmed the “cohort effect”: higher seroprevalence was observed in the older population. No association was found between H. pylori seroprevalence and dyspeptic symptoms.
The high seroprevalence of anti-H. pylori IgG in Lithuania, a country with a high incidence of gastric cancer, further raises the question of whether population-based or age-group-specific GC screening strategies—such as “screen-and-treat” for H. pylori—should be introduced to reduce the incidence and burden of GC.

Author Contributions

Conceptualization, L.K., V.L., E.C., J.K. and J.P.; methodology, E.C., J.P., V.S., V.L. and D.L.; formal analysis, J.P. and E.C.; investigation, E.C., J.P., D.L. and V.S.; resources, V.S. and D.L.; data curation, E.C., J.P., V.S., D.L. and P.J.; writing—original draft preparation, P.J., E.C., M.K. and J.P.; writing—review and editing, P.J., J.P., L.J., L.K. and V.L.; visualization, E.C., P.J., J.P. and L.J.; supervision, J.P., J.K., L.K. and V.L.; project administration, J.P., J.K., L.K. and V.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted according to the guidelines of the Declaration of Helsinki. The study was approved by the Kaunas Regional Biomedical Research Ethics Committee (protocol number BE-2-49, issued on 5 June 2018).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
H. pyloriHelicobacter pylori
GCGastric cancer
PUDPeptic ulcer disease
IgGImmunoglobulin G
IARCInternational Agency for Research on Cancer
GLOBOCANGlobal Cancer Observatory
95% CI95% confidence interval
OROdds ratio

References

  1. Malfertheiner, P.; Megraud, F.; Rokkas, T.; Gisbert, J.P.; Liou, J.-M.; Schulz, C.; Gasbarrini, A.; Hunt, R.H.; Leja, M.; O’Morain, C. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut 2022, 71, 1724–1762. [Google Scholar] [CrossRef] [PubMed]
  2. Chey, W.D.; Howden, C.W.; Moss, S.F.; Morgan, D.R.; Greer, K.B.; Grover, S.; Shah, S.C. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am. J. Gastroenterol. 2024, 119, 1730–1753. [Google Scholar] [CrossRef] [PubMed]
  3. Malfertheiner, P.; Camargo, M.C.; El-Omar, E.; Liou, J.-M.; Peek, R.; Schulz, C.; Smith, S.I.; Suerbaum, S. Helicobacter pylori infection. Nat. Rev. Dis. Prim. 2023, 9, 19. [Google Scholar] [CrossRef]
  4. Ahn, H.J.; Lee, D.S. Helicobacter pylori in gastric carcinogenesis. World J. Gastrointest. Oncol. 2015, 7, 455–465. [Google Scholar] [CrossRef] [PubMed]
  5. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef]
  6. Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017, 153, 420–429. [Google Scholar] [CrossRef]
  7. Chen, Y.-C.; Malfertheiner, P.; Yu, H.-T.; Kuo, C.-L.; Chang, Y.-Y.; Meng, F.-T.; Wu, Y.-X.; Hsiao, J.-L.; Chen, M.-J.; Lin, K.-P.; et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology 2024, 166, 605–619. [Google Scholar] [CrossRef]
  8. Brown, L.M. Helicobacter pylori: Epidemiology and routes of transmission. Epidemiol. Rev. 2000, 22, 283–297. [Google Scholar] [CrossRef]
  9. Leja, M.; Cine, E.; Rudzite, D.; Vilkoite, I.; Huttunen, T.; Daugule, I.; Rumba-Rozenfelde, I.; Pimanov, S.; Liepniece-Karele, I.; Pahomova, J.; et al. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. Eur. J. Gastroenterol. Hepatol. 2012, 24, 1410–1417. [Google Scholar] [CrossRef]
  10. Thjodleifsson, B.; Asbjörnsdottir, H.; Sigurjonsdottir, R.B.; Gíslason, D.; Olafsson, I.; Cook, E.; Jogi, R.; Janson, C. Seroprevalence of Helicobacter pylori and cagA antibodies in Iceland, Estonia and Sweden. Scand. J. Infect. Dis. 2007, 39, 683–689. [Google Scholar] [CrossRef]
  11. Celiński, K.; Kurzeja-Mirosław, A.; Słomka, M.; Cichoz-Lach, H.; Madro, A.; Kasztelan-Szczerbińska, B. The effects of environmental factors on the prevalence of Helicobacter pylori infection in inhabitants of Lublin Province. Ann. Agric. Environ. Med. 2006, 13, 185–191. [Google Scholar] [PubMed]
  12. Ruibys, G.; Denapiene, G.; Wright, R.A.; Irnius, A. Prevalence of Helicobacter pylori Infection in Lithuanian Children. Am. J. Gastroenterol. 2004, 99, S32. Available online: https://journals.lww.com/ajg/Fulltext/2004/10001/PREVALENCE_OF_HELICOBACTER_PYLORI_INFECTION_IN.95.aspx (accessed on 17 March 2025). [CrossRef]
  13. Kupcinskas, J.; Leja, M. Management of Helicobacter pylori-Related Diseases in the Baltic States. Dig. Dis. 2014, 32, 295–301. Available online: https://www.karger.com/DOI/10.1159/000357862 (accessed on 16 March 2025). [CrossRef] [PubMed]
  14. Jonaitis, L.; Ivanauskas, A.; Janciauskas, D.; Funka, K.; Sudraba, A.; Tolmanis, I.; Krams, A.; Stirna, D.; Vanags, A.; Kupcinskas, L.; et al. Precancerous gastric conditions in high Helicobacter pylori prevalence areas: Comparison between Eastern European (Lithuanian, Latvian) and Asian (Taiwanese) patients. Medicina 2007, 43, 623–629. [Google Scholar] [CrossRef]
  15. Jonaityte, I.R.; Ciupkeviciene, E.; Jonaitis, P.; Kupcinskas, J.; Petkeviciene, J.; Jonaitis, L. Changes in the Seroprevalence of Helicobacter pylori among the Lithuanian Medical Students over the Last 25 Years and Its Relation to Dyspeptic Symptoms. Medicina 2021, 57, 254. [Google Scholar] [CrossRef]
  16. Leja, M. Where are we with gastric cancer screening in Europe in 2024? Gut 2024, 73, 2074–2082. [Google Scholar] [CrossRef]
  17. Jonaitis, P.; Kupčinskas, J.; Nyssen, O.P.; Puig, I.; Gisbert, J.P.; Jonaitis, L.V. Evaluation of the Effectiveness of Helicobacter Pylori Eradication Regimens in Lithuania During the Years 2013–2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Medicina 2021, 57, 642. [Google Scholar] [CrossRef]
  18. Laszewicz, W.; Iwańczak, F.; Iwańczak, B. Seroprevalence of Helicobacter pylori infection in Polish children and adults depending on socioeconomic status and living conditions. Adv. Med. Sci. 2014, 59, 147–150. [Google Scholar] [CrossRef]
  19. Kondratiuk, N.; Paliy, I.; Zaika, S. Analysis of the prevalence of Helicobacter pylori infection and the effectiveness of eradication schemes in patients with the upper gastrointestinal tract disorders (according to the results of 13C-urea breath tests for 2006–2019). Prz. Gastroenterol. 2021, 16, 229–234. [Google Scholar] [CrossRef]
  20. Razuka-Ebela, D.; Polaka, I.; Parshutin, S.; Santare, D.; Ebela, I.; Murillo, R.; Tzivian, L.; Park, J.Y.; Leja, M. Sociodemographic, Lifestyle and Medical Factors Associated with Helicobacter pylori Infection. J. Gastrointest. Liver Dis. 2020, 29, 319–327. [Google Scholar] [CrossRef]
  21. Taylor, C.S.; McMahon, M.V.; Ward, Z.J.; Alarid-Escudero, F.; Camargo, M.C.; Laszkowska, M.; Roa, J.; Yeh, J.M. Birth cohort and age-specific trends in global Helicobacter pylori seroprevalence: A scoping review. Lancet Reg. Health-Am. 2025, 41, 100877. Available online: https://www.sciencedirect.com/science/article/pii/S2667193X24002047 (accessed on 17 March 2025). [CrossRef] [PubMed]
  22. Wernly, S.; Semmler, G.; Rezar, R.; Schaffler-Schaden, D.; Flamm, M.; Aigner, E.; Datz, C.; Wernly, B. Assessing the association between H. pylori infection and educational status: Implications for screening strategies? Minerva Gastroenterol. 2024, 70, 171–176. [Google Scholar] [CrossRef] [PubMed]
  23. Park, J.S.; Jun, J.S.; Seo, J.-H.; Youn, H.-S.; Rhee, K.-H. Changing prevalence of Helicobacter pylori infection in children and adolescents. Clin. Exp. Pediatr. 2021, 64, 21–25. [Google Scholar] [CrossRef]
  24. Li, Y.; Choi, H.; Leung, K.; Jiang, F.; Graham, D.Y.; Leung, W.K. Global prevalence of Helicobacter pylori infection between 1980 and 2022: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2023, 8, 553–564. [Google Scholar] [CrossRef]
  25. Borka Balas, R.; Meliț, L.E.; Mărginean, C.O. Worldwide Prevalence and Risk Factors of Helicobacter pylori Infection in Children. Children 2022, 9, 1359. [Google Scholar] [CrossRef]
  26. Amaral, O.; Fernandes, I.; Veiga, N.; Pereira, C.; Chaves, C.; Nelas, P.; Silva, D. Living Conditions and Helicobacter pylori in Adults. Biomed Res. Int. 2017, 2017, 9082716. [Google Scholar] [CrossRef]
  27. Contreras, M.; Fernández-Delgado, M.; Reyes, N.; García-Amado, M.A.; Rojas, H.; Michelangeli, F. Helicobacter pylori Infection in Rural and Urban Dyspeptic Patients from Venezuela. Am. J. Trop. Med. Hyg. 2015, 93, 730–732. [Google Scholar] [CrossRef]
  28. Rosenstock, S.; Kay, L.; Rosenstock, C.; Andersen, L.P.; Bonnevie, O.; Jørgensen, T. Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes. Gut 1997, 41, 169–176. [Google Scholar] [CrossRef]
  29. Marzio, L.; Cappello, G.; Ballone, E. Evaluation of dyspeptic symptoms in patients with and without Helicobacter pylori infection and normal upper gastrointestinal endoscopy. Dig. Liver Dis. 2003, 35, 138–142. [Google Scholar] [CrossRef]
  30. O’Connor, A.; O’Morain, C.A.; Ford, A.C. Population screening and treatment of Helicobacter pylori infection. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 230–240. [Google Scholar] [CrossRef]
  31. Januszewicz, W.; Turkot, M.H.; Malfertheiner, P.; Regula, J. A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When? Cancers 2023, 15, 664. [Google Scholar] [CrossRef] [PubMed]
  32. Chiang, T.-H.; Cheng, H.-C.; Chuang, S.-L.; Chen, Y.-R.; Hsu, Y.-H.; Hsu, T.-H.; Lin, L.-J.; Lin, Y.-W.; Chu, C.-H.; Wu, M.-S.; et al. Mass screening and eradication of Helicobacter pylori as the policy recommendations for gastric cancer prevention. J. Formos. Med. Assoc. 2022, 121, 2378–2392. Available online: https://www.sciencedirect.com/science/article/pii/S0929664622003229 (accessed on 14 March 2025). [CrossRef] [PubMed]
Figure 1. The frequency of gastrointestinal complaints in the past 30 days according to the presence of H. pylori antibodies, p > 0.05.
Figure 1. The frequency of gastrointestinal complaints in the past 30 days according to the presence of H. pylori antibodies, p > 0.05.
Medicina 61 01049 g001
Table 1. Sociodemographic and environmental characteristics of the study participants.
Table 1. Sociodemographic and environmental characteristics of the study participants.
CharacteristicsMalesFemalesTotalp-Value Between Males and Females
n%n%n%
Age group (years)
25–3410119.27815.017917.10.062
35–4414928.312824.627726.5
45–5412423.614928.727326.1
55–6915228.916531.731730.3
Level of education
Basic19437.013025.133431.1<0.001
Intermediate407.66312.21039.9
Advanced29155.432562.761659.0
Place of residence in childhood
Urban40577.138674.579175.80.322
Rural12022.913225.525224.2
Drinking water from municipal supply in childhood
Yes39575.237873.077374.10.404
No13024.814027.027025.9
Hot tap water in childhood
Yes39875.837071.476873.60.108
No12724.214828.627526.4
Number of household members in childhood
2–311221.310119.521320.40.044
426650.623445.250047.9
5 and more14828.118335.333131.7
Table 2. Seroprevalence of H. pylori among different age groups and genders of Kaunas city residents.
Table 2. Seroprevalence of H. pylori among different age groups and genders of Kaunas city residents.
Age GroupsMales (n = 472)Females (n = 442)Total (n = 914)
HP-NegativeHP-PositiveHP-NegativeHP-PositiveHP-NegativeHP-Positive
n%n%n%n%n%n%
25–344852.2 a4447.8 a3752.1 c3447.9 c8552.1 c7847.9 c
35–445037.9 b8262.1 b3935.17264.98936.615463.4
45–542623.4 b8576.6 b3932.88067.26528.316571.7
55–692719.7 *11080.3 *5639.78560.38329.919570.1
Total non-standardized15132.0 *32168.0 *17138.727161.332235.259264.8
Total age-standardized, %
(95% CI)
33.7
(27.8–36.2)
66.3
(62.3–70.8)
39.8
(34.2–43.2)
60.2
(55.8–65.0)
36.9
(32.1–38.3)
63.1
(60.4–66.7)
HP: Helicobacter pylori; * p < 0.05 compared to females; a p < 0.05 compared to the 45–54 and 55–64 age groups; b p < 0.05 compared to the 55–69 age group; c p < 0.05 compared to other age groups (Z-test with Bonferroni correction); 95% CI: 95% confidence interval.
Table 3. Prevalence of H. pylori antibodies in relation to analyzed independent factors.
Table 3. Prevalence of H. pylori antibodies in relation to analyzed independent factors.
CharacteristicsHP+HP−p-Value
n%n%
Education
Basic21673.2 a7926.8<0.001
Intermediate4957.63642.4
Advanced32561.120738.9
Childhood living environment
Urban44263.525436.50.178
Rural14868.56831.5
Drinking water sourced from a municipal supply
Yes41963.325437.70.010
No17171.56828.5
Childhood access to hot water
Yes41862.425237.60.015
No17271.17028.9
Number of household members in childhood
2–311260.97239.10.353
428364.615535.4
5 and more19667.49532.6
HP+: antibodies against H. pylori detected; HP−: antibodies against H. pylori not detected. a p < 0.05, compared to intermediate and advanced education in the HP+ group (Z-test with Bonferroni correction).
Table 4. Odds ratios of H. pylori infection in relation to analyzed factors (univariable and multivariable logistic regression analyses).
Table 4. Odds ratios of H. pylori infection in relation to analyzed factors (univariable and multivariable logistic regression analyses).
FactorsUnivariable AnalysisMultivariable Analysis
OR95% CIp-ValueOR95% CIp-Value
Sex
Females1 1
Males1.341.02–1.760.0341.321.0–1.750.049
Age *1.031.02–1.04<0.0011.031.01–1.04<0.001
Education
Basic1 1
Intermediate0.500.30–0.820.0060.450.27–0.750.002
Advanced0.570.42–0.78<0.0010.650.47–0.890.008
Childhood living environment
Urban1 1
Rural1.250.90–1.730.1791.030.72–1.480.876
Drinking water sourced from a municipal supply
Yes1 1
No1.481.08–2.040.0161.200.64–1.570.399
Childhood access to hot water
Yes1 1
No1.521.11–2.100.0100.980.64–1.510.931
* Change in odds ratio per one-year increase in age; 95% CI: 95% confidence interval.
Table 5. Distribution of study subjects based on previous H. pylori serologic testing.
Table 5. Distribution of study subjects based on previous H. pylori serologic testing.
History of H. pylori Serologic TestingMalesFemalesTotalp-Value Between Males and Females
n%n%n%
Not tested39575.234265.873770.5<0.001
Tested—negative479.07414.212111.6
Tested—positive6111.69618.515715.0
Unknown224.281.5302.9
Total5251005201001046100
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Jonaitis, P.; Petkeviciene, J.; Salteniene, V.; Ciupkeviciene, E.; Jonaitis, L.; Kriukas, M.; Luksiene, D.; Lesauskaite, V.; Kupcinskas, J.; Kupcinskas, L. Helicobacter pylori Seroprevalence and Its Associations with Sociodemographic Characteristics, Environmental Factors, and Gastrointestinal Complaints: A Cross-Sectional Study in the Adult Population of Kaunas City, Lithuania. Medicina 2025, 61, 1049. https://doi.org/10.3390/medicina61061049

AMA Style

Jonaitis P, Petkeviciene J, Salteniene V, Ciupkeviciene E, Jonaitis L, Kriukas M, Luksiene D, Lesauskaite V, Kupcinskas J, Kupcinskas L. Helicobacter pylori Seroprevalence and Its Associations with Sociodemographic Characteristics, Environmental Factors, and Gastrointestinal Complaints: A Cross-Sectional Study in the Adult Population of Kaunas City, Lithuania. Medicina. 2025; 61(6):1049. https://doi.org/10.3390/medicina61061049

Chicago/Turabian Style

Jonaitis, Paulius, Janina Petkeviciene, Violeta Salteniene, Egle Ciupkeviciene, Laimas Jonaitis, Mantas Kriukas, Dalia Luksiene, Vaiva Lesauskaite, Juozas Kupcinskas, and Limas Kupcinskas. 2025. "Helicobacter pylori Seroprevalence and Its Associations with Sociodemographic Characteristics, Environmental Factors, and Gastrointestinal Complaints: A Cross-Sectional Study in the Adult Population of Kaunas City, Lithuania" Medicina 61, no. 6: 1049. https://doi.org/10.3390/medicina61061049

APA Style

Jonaitis, P., Petkeviciene, J., Salteniene, V., Ciupkeviciene, E., Jonaitis, L., Kriukas, M., Luksiene, D., Lesauskaite, V., Kupcinskas, J., & Kupcinskas, L. (2025). Helicobacter pylori Seroprevalence and Its Associations with Sociodemographic Characteristics, Environmental Factors, and Gastrointestinal Complaints: A Cross-Sectional Study in the Adult Population of Kaunas City, Lithuania. Medicina, 61(6), 1049. https://doi.org/10.3390/medicina61061049

Article Metrics

Back to TopTop